Seeing Is Believing
Currently out of the existing stock ratings of Dane Leone, 109 are a BUY (83.85%), 19 are a HOLD (14.62%), 2 are a SELL (1.54%).
Analyst Dane Leone, currently employed at RAYMOND JAMES, carries an average stock price target met ratio of 55.5% that have a potential upside of 35.22% achieved within 225 days.
Dane Leone’s has documented 227 price targets and ratings displayed on 32 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on XLO, Xilio Development at 08-Nov-2024.
Analyst best performing recommendations are on NKTX (NKARTA ).
The best stock recommendation documented was for BBIO (BRIDGEBIO PHARMA) at 12/28/2021. The price target of $17 was fulfilled within 6 days with a profit of $3.57 (26.58%) receiving and performance score of 44.3.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
1 months 8 days ago
(22-Sep-2025)
0/4 (0%)
$23.75 (380.00%)
Buy
2 months 18 days ago
(12-Aug-2025)
3/4 (75%)
$30.52 (321.94%)
884
Buy
$12
$7.93 (194.84%)
$16
4 months 6 days ago
(24-Jun-2025)
1/4 (25%)
$9.42 (365.12%)
292
Hold
$4
$-0.07 (-1.72%)
$5
5 months 16 days ago
(14-May-2025)
3/5 (60%)
$1.95 (95.12%)
127
Buy
$6
$4.05 (207.69%)
$4
2 years 1 months 26 days ago
(05-Sep-2023)
4/7 (57.14%)
$4.22 (237.08%)
196
What Year was the first public recommendation made by Dane Leone?